You are here: Industry Insights > cystic fibrosis

News List

Proteostasis Therapeutics Initiates Global Cystic Fibrosis Phase 2 Study americanpharmaceuticalreview
July 26, 2019
Proteostasis Therapeutics announced that the first patient has been dosed in the Company's 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heteroz
Vertex Submits NDA for Triple Combination of VX-445, Tezacaftor, Ivacaftor in Cystic Fibrosis americanpharmaceuticalreview
July 23, 2019
Vertex Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.
Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union firstwordpharma
April 11, 2019
Synspira Therapeutics today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal ……
EC approves Vertex’s Orkambi for children with cystic fibrosis pharmaceutical-technology
January 23, 2019
Vertex Pharmaceuticals has received approval from the European Commission (EC) to expand the indication of its Orkambi to treat paediatric patients suffering from cystic fibrosis (CF)....
Vertex wins European approval for new cystic fibrosis combination pharmaphorum
December 17, 2018
European regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi.The European Commission’s greenlight for Symkevi (tezacaftor/ivacaftor) will allow.....
Blood tests could lead to personalised cystic fibrosis treatment europeanpharmaceuticalreview
December 14, 2018
A blood test could transform the way doctors treat people affected by cystic fibrosis, helping to personalise treatments to individual people…
Inhaling Hypertonic Saline May Aid Infants With Cystic Fibrosis drugs
December 14, 2018
In infants with cystic fibrosis (CF), preventive inhalation with hypertonic saline (HS) during the first months of life is safe and well tolerated and .....
Kalydeco approved by EU for CF in 12-14 month olds pharmatimes
November 30, 2018
Vertex Pharmaceuticals says the European Commission has granted approval of the label extension for Kalydeco, to include the treatment of patients with cystic fibrosis (CF) aged 12 to 24 months.
EC approves Vertex’s Symkevi for cystic fibrosis pharmaceutical-technology
November 05, 2018
The European Commission has approved London-based Vertex’s Symkevi (ivacaftor+tezacaftor) in combination with ivacaftor for patients with specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Santhera’s cystic fibrosis drug POL6014 in line for orphan status pharmatimes
October 19, 2018
Santhera says its experimental cystic fibrosis drug POL6014 is likely to be designated an orphan drug in the next 30 days, putting the firm in line to receive...

Previous page 1 2 3 4 5 6 Next page